{"id":8,"date":"2024-04-04T02:59:08","date_gmt":"2024-04-03T23:59:08","guid":{"rendered":"https:\/\/sisu.ut.ee\/gentransmed\/seminars\/"},"modified":"2024-04-04T02:59:17","modified_gmt":"2024-04-03T23:59:17","slug":"seminars","status":"publish","type":"page","link":"https:\/\/sisu.ut.ee\/gentransmed\/seminars\/","title":{"rendered":"Seminars of the Centre of Excellence for Genomics and Translational Medicine"},"content":{"rendered":"
\r\n\t

\r\n\t\tGenoomika ja Siirdemeditsiini korraldab kord kuus toimuvat seminaride sarja, mida on oodatud kuulama k\u00f5ik arstid, teadurid, noorteadlased ja tudengid.\r\n\t<\/h2>\r\n\r\n\t

\r\n\t\tGuest seminar of the CoE for Genomics and Translational Medicine to be held by Professor Sir Rory Collins (UK), on October 4th, at 11:00 (Omicum building, room 105)<\/strong>\r\n\t<\/p>\r\n\r\n\t

\r\n\t\tThe next Guest Seminar of the CoE for Genomics and Translational Medicine will be held on October 4th, at 11:00 \u00a0(Omicum building, room 105) \u00a0by Professor Sir Rory Collins (Professor of Medicine & Epidemiology, University of Oxford; and Principal Investigator of UK Biobank).
Biography:<\/strong> \u00a0Rory Collins studied Medicine at St Thomas\u2019s Hospital Medical School, London University, and Statistics at George Washington University and at Oxford University. In 1985, he became co-director, with Professor Sir Richard Peto, of the University of Oxford\u2019s Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU). In 1996, he was appointed Professor of Medicine and Epidemiology at Oxford, supported by the British Heart Foundation.
He became Principal Investigator and Chief Executive of the UK Biobank prospective study of 500,000 people in 2005. From July 2013, he became the Head of the Nuffield Department of Population Health at Oxford University.
Title of the talk: \u201d The need for large prospective studies in different populations\u201d.<\/strong>
Date and place: October 4th, at 11:00, Omicum building, room 105.<\/strong>\u00a0
The Centre of Excellence for Genomics and Translational Medicine is funded by EU European Regional Development Fund (Project No.2014-2020.4.01.15-0012).<\/em>\r\n\t<\/p>\r\n\r\n\t

\r\n\t\t
Guest Seminar of the CoE of Genomics and Translational Medicine to be held by <\/span>Prof. Karl Bechte<\/span><\/span><\/span><\/b>r, May 2, 2019<\/span><\/span><\/span><\/b>
Prof. Dr. Karl Bechter is a Professor in Psychiatry in Ulm University, Germany since 2003 and the head of Department of Psychotherapeutic Medicine and Psychosomatics in the Department of Psychiatry II, Ulm University since 1998. He has received several national and international scientific awards and appointments and is holding research funding from M. Ammonstiftung Munich and EU Horizon2020 project on mood stratification. His major medical research activity focuses on the connection between immunology and psychiatry.<\/span><\/span>

T<\/span><\/b><\/span>itle: Update on the mild encephalitis hypothesis of severe mental disorders \u2013 with a look on the role of CSF flow<\/span><\/span><\/b>

Time<\/b>: 2.5.2019, Thu, 10am-12pm<\/span>\r\n\t<\/p>\r\n\r\n\t

\r\n\t\tPlace<\/span><\/b>: Ravila 19, Biomedicum, Schmidt center, room nr 1088\/1089<\/span><\/span>

Abstract<\/span><\/span><\/b>: Mild encephalitis (ME) may underly a subgroup of severe mental disorders, especially from the affective and schizophrenic spectrum (Bechter 2001 & 2013). After the discovery of NMDAR autoantibodies by Dalmau et al in 2007, and with an emerging variety of other CNS autoantibodies, an increasing number of neurological disorders appeared attributable to CNS autoantibody pathology. In some cases, CNS autoantiboy production follows previous infection, e.g. Herpes virus encephalitis. With this recent development in neurology, the plausibility of the ME hypothesis for severe mental disorders is also increasing. A large and recently emerging number of findings support such pathophysiological type of autoimmune sychosis in the sense of ME hypothesis. Primary site of immune-inflammatory pathology appears to be the brain, but also systemic pathology has been found in schizophrenia and depression, e.g. muscle lesions. CSF outflow along peripheral nerves, which remained however ignored in a pathophysiological scenario up to now, may be involved. We recently found that even CSF cells can follow this peripheral CSF outflow pathway. Also, exosomes and other microparticles must be considered in such scenario with important consequences in systemic symptoms of neuroinflammation in general.<\/span><\/span>

Selected publications<\/span><\/span><\/b>\r\n\t<\/p>\r\n\r\n\t